Department of Neurology, CHU Nîmes, Hôpital Caremeau, Place du Pr Debré, 30029 Nîmes Cedex 4, France.
Neuromuscul Disord. 2013 Jul;23(7):599-601. doi: 10.1016/j.nmd.2013.03.014. Epub 2013 Apr 30.
Myocardial infarction after rituximab or other monoclonal antibody therapies has been reported in rare cases, all in patients with classical cardiovascular risk factors or associated inflammatory or lymphoproliferative disorders. We report the case of a 52-year-old man, without classical cardiovascular risk factors or associated inflammatory or lymphoproliferative disorder, treated for seronegative myasthenia with rituximab infusions complicated by myocardial infarction. The exact origin of myocardial infarction after monoclonal antibody treatment is unclear. Myocardial infarction is a rare but possibly fatal complication of rituximab infusion, even occurring in relatively young patients, without classical risk factors and without associated inflammatory or lymphoproliferative disorder.
已有报道称，在极少数情况下，使用利妥昔单抗或其他单克隆抗体治疗后会发生心肌梗死，所有这些患者均具有典型的心血管危险因素或伴有炎症或淋巴增生性疾病。我们报告了一例 52 岁男性病例，该患者无典型心血管危险因素或伴发炎症或淋巴增生性疾病，因血清阴性肌无力而接受利妥昔单抗输注治疗，后并发心肌梗死。单克隆抗体治疗后心肌梗死的确切病因尚不清楚。心肌梗死是利妥昔单抗输注的一种罕见但可能致命的并发症，即使发生在相对年轻的患者中，也无典型的危险因素，也无相关炎症或淋巴增生性疾病。
